Genmab A/S
Genmab A/S (GMAB) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · GMAB · as of Mar 31, 2025
Ownership Breakdown
228
Institutional Holders
▼ 5 vs Q4
$1.28B
Total Inst. Value
▲ $10.24M vs Q4
613.93M
Shares Outstanding
freeFloat 98.78%
64.90M
13F Shares Held
▲ 4.10M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
GMAB largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ALLIANCEBERNSTEIN L.P. pharmaceutical preparations | 14.73M | 23.11% | 23.11% | $288.32B | May 15, 2025 | ▼ 210.1K |
ORBIS ALLAN GRAY LTD pharmaceutical preparations | 5.71M | 8.96% | 8.96% | $111.82B | May 15, 2025 | ▲ 2.90M |
CITADEL ADVISORS LLC pharmaceutical preparations | 4.43M | 6.95% | 6.95% | $86.67B | May 15, 2025 | ▲ 1.33M |
BLACKROCK, INC. pharmaceutical preparations | 3.52M | 5.52% | 5.52% | $68.88B | May 2, 2025 | ▼ 680.6K |
HARDING LOEVNER LP pharmaceutical preparations | 2.88M | 4.52% | 4.52% | $56.44B | May 15, 2025 | ▲ 637.4K |
MORGAN STANLEY pharmaceutical preparations | 2.84M | 4.45% | 4.45% | $55.59B | May 15, 2025 | ▲ 33.0K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 2.26M | 3.55% | 3.55% | $44.30B | May 14, 2025 | ▲ 336.2K |
MARSHALL WACE, LLP pharmaceutical preparations | 2.18M | 3.42% | 3.42% | $42.71B | May 15, 2025 | ▲ 1.06M |
TWO SIGMA ADVISERS, LP pharmaceutical preparations | 1.97M | 3.10% | 3.10% | $38.65B | May 15, 2025 | ▲ 320.2K |
TWO SIGMA INVESTMENTS, LP pharmaceutical preparations | 1.90M | 2.98% | 2.98% | $37.20B | May 15, 2025 | ▲ 193.4K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
32
Increased
+12.22M shares4
New Positions
first time holders13
Decreased
−2.79M shares0
Sold Out
fully exitedNet shares change (top 50)
+9.42M
+12.22M / −2.79M
Net new holders
+23
4 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
GMAB insider trading · insider activity
Source: SEC Form 4
Recent Insider Transactions
Showing 10 most recent · Common Stock only
No recent insider transactions reported.
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Genmab A/S (GMAB) is primarily owned by institutional investors, who hold approximately 10.6% of total shares outstanding. Company insiders own approximately 1.22%, while retail and public investors account for the remaining 88.21%.
The largest institutional shareholder of Genmab A/S is ALLIANCEBERNSTEIN L.P., holding approximately 14.73 million shares — equal to 23.11% of outstanding shares — as of March 31, 2025.
A total of 228 institutional investors currently hold GMAB stock, with a combined institutional value of approximately $1.28 billion as of the most recent 13F filing period.
Frequently asked questions
GMAB ownershipGenmab A/S (GMAB) is primarily owned by institutional investors, who hold approximately 10.6% of shares. The largest shareholder is ALLIANCEBERNSTEIN L.P. with a 23.11% stake. Company insiders hold 1.22%. Data sourced from SEC Form 13F as of March 31, 2025.